Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer
Status:
Not yet recruiting
Trial end date:
2023-04-30
Target enrollment:
Participant gender:
Summary
This phase II trial studies the side effects of chemotherapy and intensity modulated
radiation therapy in treating patients with low-risk HIV-associated anal cancer, and
nivolumab after standard of care chemotherapy and radiation therapy in treating patients with
high-risk HIV-associated anal cancer. Radiation therapy uses high energy x-rays to kill tumor
cells and shrink tumors. Chemotherapy drugs, such as mitomycin, fluorouracil, and
capecitabine, work in different ways to stop the growth of tumor cells, either by killing the
cells, by stopping them from dividing, or by stopping them from spreading. Giving
chemotherapy with radiation therapy may kill more tumor cells. Immunotherapy with monoclonal
antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may
interfere with the ability of tumor cells to grow and spread. Giving nivolumab after standard
of care chemotherapy and radiation therapy may help reduce the risk of the tumor coming back.